Article Text
Statistics from Altmetric.com
Jean Claude Juncker performs U-turn on EU pharmaceutical responsibilities
Following pressure from healthcare NGOs, including EAHP, European Union (EU) Commission President Jean Claude Juncker has reversed his previous plan to place responsibility for EU pharmaceutical issues with the Directorate General for Enterprise and will instead leave these under the authority of the Directorate General responsible for healthcare matters.
However, he did not change his plans in respect of medical device matters. Responsibility for EU considerations in this area, including a proposal to overhaul the existing EU regulations, will rest with the Enterprise Directorate General.
European Medicines Agency chief steps down after court case
Guido Rasi's 3-year leadership of the European Medicines Agency (EMA) has come to a premature end after a European court annulled his appointment.
The European Union Civil Service Tribunal ruled that Rasi's 2011 selection as executive director of the regulator in 2011 was deemed invalid after a case was made against the selection procedure.
Deputy executive director Andreas Pott will take the helm on a temporary basis while the EMA and the European Commission take legal advice as to the next steps.
European Commission seeks opinion on changes to the Working Time Directive
The European Commission has issued an online public consultation asking how the Working Time Directive (WTD) should be changed. Responses to …
Footnotes
-
Competing interests None.
-
Provenance and peer review Commissioned; internally peer reviewed.